Japonium Sponsor Magritek - MRI & NMR for everyone, everywhere
Prof. Henri Moissan (1852-1907) - Paris
Prof. Anatole Abragam (1914-2011) - CEA (Saclay, France)
Prof. Louis Néel (1904-2000) - CEA (Grenoble, France)
- Creation of the Scientific Polygon in Grenoble (1956): CENG, ILL, ESRF, etc...
- Creation of a Physical Organic Chemistry laboratory (COP)
by 2 young chemists from ENS (Paris):
* Prof. Didier Gagnaire (1930-2014) - CEA (Grenoble)
Nuclear Magnetic Resonance (NMR) - Carbohydrates
Founder of CERMAV (1966)
* Prof. André Rassat (1932-2005) - CEA (Grenoble)
Electron Spin Resonance (ESR) - Nitroxides
Prof. Harden McConnell (1927-2014) - Stanford (USA)
Dr. Francis Cinget (Ph.D. Thesis) - CEA (Grenoble)
Double Spin Labeling in the D-Glucose Series: Perturbation of the Spin-Lattice Relaxation Time in 13C and 19F NMR by a Nitroxide Radical: Probe for Intramolecular Distances.
Dr. Francis Cinget & Prof. Tomoya Ogawa - RIKEN (Wako, Japan)
Prof. Stephen Fesik - Abbott (USA)
Dr. Francis Cinget - Sumitomo Pharmaceuticals (Osaka, Japan)
1995~ NMR-based Conformational Analysis of Bio-active Oligosaccharides
1997~ NMR-based Fragment-based Drug Design (FBDD)
Dr. Wolfgang Jahnke - Novartis (Basel, Switzerland)
Dr. Claudio Dalvit - Nerviano Medical Sciences (Milano, Italy)
B-Raf (Plexxikon / Roche)
Selective Bcl-2 (AbbVie)
1976~ started Laboratory Sciences: Physics, Chemistry, Biology (Reims - France)
1983~ started NMR (Prof. M. L. Martin - Nantes, France / Co-founder of Eurofins Scientific)
1986~ started Carbohydrates (Prof. Jacques Gelas - Clermont-Ferrand, France)
1995~ started NMR-based Drug Design (Sumitomo Pharmaceuticals - Osaka, Japan)
2006~ started NEW SCIENTIFIC PLATFORM (SynphaTec Japon Co., Ltd. - Osaka, Japan)
2016~ started NEW PACKAGE COMBINING KEY DISRUPTIVE INNOVATIONS (FBT3D)
NMR-based Fragment-based Theranostic Design, Discovery and Development (FBT3D)
Explore, develop and apply our robust NMR-based FBT3D package to tackle key therapeutic targets of interest and help our customers to discover new drugs more efficiently. In parallel to this, our efforts are continuously directed towards the improvement of personalized medicine.
Bridging Smart R&D Services Worldwide
Build-up a multi-disciplinary portfolio of services based on external expertise and know-how to complement our internal scientific background, expertise and know-how.
Create, develop and optimize synergies between disruptive internal and external innovations (science, technology, expertise and know-how) to support our customers in a unique manner.
Design, set-up and launch new R&D projects to strenghten scientific collaborations between Europe and the Asia-Pacific region, especially in the global field of Life Sciences.
Ministry of Health, Labour & Welfare Research Institutes & University Laboratories
Pharmaceutical & Biotech Companies Neutraceutical & Cosmetic Companies
Agrochemical & Chemical Companies CRDMOs & Trading Companies